A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
Part of paid clinical trials in Dothan, Alabama.
- Sponsor
- Hoffmann-La Roche
- Study ID
- NCT06589986
- Phase
- PHASE3
- Status
- Active Not Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 16 Years - 80 Years
- Healthy Volunteers
- Not accepted
Interventions
- Afimkibart — DRUGAfimkibart will be administered as IV infusion. Afimkibart will be administered as SC injection.
- Placebo — DRUGPlacebo matching IV afimkibart. Placebo matching SC afimkibart.
Study Details
This Phase III, multicenter, double-blind, placebo-controlled, treat-through study will evaluate the efficacy and safety of Afimkibart (RO7790121) compared with placebo in participants with moderately to severely active ulcerative colitis (UC).
Key Dates
- First listed
- Sep 19, 2024
- Start date
- Sep 17, 2024
- Status verified
- Jun 2026
- Primary completion
- Jan 30, 2027
- Completion
- Jan 30, 2031
Study Design
- Enrollment
- 400 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: AfimkibartParticipants will receive afimkibart intravenously (IV) followed by afimkibart subcutaneous (SC) injection.
- Placebo Comparator: PlaceboParticipants will receive placebo IV followed by placebo SC.
Primary Outcome Measure
Percentage of Participants with Clinical Remission at Week 12 [ Time Frame: At Week 12 ]
Locations (58)
Find similar trials in Dothan, AL
Nationwide
By condition
By research site
Digestive Health Specialists of the Southeast (Gastroenterology Associates of Dothan) - Dothan· Dothan, ALOm Research LLC· Lancaster, CAUniversity of California Irvine· Orange, CAAmicis Research Center· Santa Clarita, CAPeak Gastroenterology Associates· Colorado Springs, COAccess Research Institute· Brooksville, FL
Related Studies
- A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative ColitisPHASE3 · Recruiting · Hoffmann-La Roche · Dothan, Alabama
- A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative ColitisPHASE3 · Recruiting · Hoffmann-La Roche · Tampa, Florida